Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech

Sandoz will pay up to $77 million upfront to Shanghai Henlius Biotech for global rights to three biosimilar drugs targeting cholesterol, lupus, and colorectal cancer. The deal includes milestone payments and is part of Sandoz's strategy to capture a large share of the global biosimilar market.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.